SI-BONE Announces Senior Leadership Changes and Record Quarterly Revenue

$SIBN
Medical/Dental Instruments
Health Care
Get the next $SIBN alert in real time by email

Laura Francis to Become Chief Executive Officer; Jeff Dunn to Become Executive Chairman; 
and Tony Recupero to Become President.

SANTA CLARA, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN) (“SI-BONE” or the “Company”), a Silicon Valley-based medical device company focused on the development of implantable devices used in the surgical treatment of the sacropelvic anatomy, today announced its intention to appoint Laura Francis as Chief Executive Officer and to the board of directors. Laura Francis currently serves as SI-BONE’s Chief Financial Officer and Chief Operating Officer. As CEO, Laura Francis will succeed Jeff Dunn, who will remain with the Company as Executive Chairman. Tony Recupero, one of the industry’s leading executives who has been with the company for the past five years as Chief Commercial Officer, will become President, Commercial Operations, heading up worldwide sales, marketing, clinical, reimbursement and medical affairs. The Company will begin a search for a new CFO immediately and senior leadership changes will occur upon the earlier of the CFO replacement or May 1, 2021.

“Laura has been an exemplary leader and operator for SI-BONE since joining the Company in 2015. She is an exceptional executive who is passionate about our mission. She is highly respected by investors and our team as well as our Board of Directors. She is committed to our principles and values and knows how to lead and execute our strategy to invest in future growth,” said Jeff Dunn. “As Executive Chairman, I look forward to remaining highly engaged with SI-BONE and its strategy, and supporting Laura in her new role as CEO.”

Laura Francis said, “I am honored and excited to lead SI-BONE during this period of unique opportunity. Now that we have addressed reimbursement, I look forward to working with Tony to invest in our growth through sales force hiring and productivity, surgeon training with our new SImulator technology, new products for sacropelvic surgical treatment, and direct to patient marketing. As a founder of the business over twelve years ago, Jeff has been a pioneer for the use of iFuse to treat sacroiliac joint dysfunction. He has left an indelible legacy and will continue to be a valuable resource as our Executive Chairman.”

Preliminary and unaudited revenue for fourth quarter 2020 is expected to be in the range of $21.9-$22.2 million, reflecting growth of 11%-12% compared to the prior year period. U.S. revenue is expected to be in the range of $20.5-$20.7 million, reflecting growth of 11%-12% compared to the prior year period. International revenue is expected to be in the range of $1.4-$1.5 million. Preliminary and unaudited revenue for full year 2020 is expected to be in the range of $73.1-$73.4 million, reflecting growth of approximately 9% over full year 2019. U.S. revenue is expected to be in the range of $67.9-$68.1 million, reflecting growth of approximately 10% compared to the prior year period. International revenue is expected to be in the range of $5.2-$5.3 million. Revenue growth in October was consistent with trends in the third quarter. Revenue also grew in November and December, but at a lower rate due to COVID-19. Cash and marketable securities are expected to be approximately $196 million as of December 31, 2020. The fourth quarter and full year 2020 revenue and cash and marketable securities included in this release are preliminary and prior to the completion of SI-BONE's financial closing procedures and audit procedures by its external auditors and therefore may be subject to adjustment. SI-BONE expects to provide fourth quarter and full year 2020 financial results during its fourth quarter 2020 earnings call in March 2021.

Impact of COVID-19 Pandemic and Financial Guidance

While SI-BONE has continued to see positive trends in its business, the Company remains mindful of the potential negative impacts due to the current increase in COVID-19 global case volumes. Given the experience of 2020 due to the pandemic, and due to the uncertain scope and duration of the pandemic, the global resurgence of cases, and uncertain timing of a global recovery and economic normalization, the Company cannot reliably estimate the future impact of the pandemic. As such, SI-BONE is unable to estimate the pandemic’s impact on operations and financial results and is not issuing 2021 financial guidance at this time.

About SI-BONE, Inc.

SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System. Studies have shown that the SI joint can be a source of pain in 15% to 30% of chronic low back pain. The iFuse Implant™, commercially available since 2009, is the only SI joint fusion device supported by multiple prospective clinical studies, including two randomized controlled trials, showing improved pain, patient function and quality of life resulting from treatment. There are over 90 peer-reviewed publications demonstrating the safety, durable effectiveness, and biomechanical and economic benefits unique to the iFuse Implant (www.si-bone.com/results). This body of evidence has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.

The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. The iFuse Implant System is also intended for sacroiliac fusion to augment stabilization and immobilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion. In addition, the iFuse Implant System is intended for sacroiliac fusion in acute, non-acute, and non-traumatic fractures involving the sacroiliac joint. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2021 SI-BONE, Inc. All Rights Reserved. 01072021

Forward Looking Statements

The preliminary unaudited financial results and statements regarding SI-BONE's continued growth and financial outlook in this press release, including SI-BONE’s expectation that it will be able to successfully invest in its future growth and the continued impact of the COVID-19 pandemic are "forward-looking" statements. These forward-looking statements are based on SI-BONE's current expectations and inherently involve significant risks and uncertainties. These risks include SI-BONE’s preliminary fourth quarter and full year 2020 revenue and cash and marketable securities, which are subject to continued review by SI-BONE and its auditors and significant adjustments may be made before final results are determined, as well as risks inherent to any leadership transition, the impact the COVID-19 pandemic will have on the ability and desire of patients and physicians to undergo procedures using the iFuse Implant System, the duration of the COVID-19 pandemic, whether the COVID-19 pandemic will recur in the future, and SI-BONE's ability to increase demand for iFuse, successfully deploy SImulators and convince surgeons to train on the SImulators, and obtain favorable coverage and reimbursement determinations from third-party payors. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these and other risks and uncertainties, many of which are described in the company's most recent filings on Form 10-K and Form 10-Q, and the Company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov), especially under the caption "Risk Factors". SI-BONE does not undertake any obligation to update forward-looking statements and expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.

Investor Contact:
Matt Bacso, CFA
investors@SI-BONE.com

Media Contact:   
Joe Powers
jpowers@si-bone.com


Get the next $SIBN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SIBN

DatePrice TargetRatingAnalyst
8/6/2024$27.00 → $19.00Buy
Needham
3/28/2024$25.00Overweight
Piper Sandler
10/12/2022$20.00Buy
Jefferies
4/7/2022$34.00Overweight
Cantor Fitzgerald
3/1/2022$30.00 → $28.00Overweight
Morgan Stanley
1/18/2022$43.00 → $36.00Buy
B of A Securities
12/21/2021$35.00 → $30.00Buy
Truist Securities
11/9/2021$42.00 → $36.00Market Outperform
JMP Securities
More analyst ratings

$SIBN
Press Releases

Fastest customizable press release news feed in the world

See more
  • SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance

    SANTA CLARA, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $49.0 million, representing growth of ~26%  U.S. revenue of $46.9 million, representing growth of ~28%Gross margin of ~79%Net loss of $4.5 million, representing an improvement of ~59%Positive adjusted EBITDA of $1.9 million, representing an improvement of ~139%Ended the quarter with $150.0 million in cash and equivalents, representing $0

    $SIBN
    Medical/Dental Instruments
    Health Care
  • Bruker Appoints Laura Francis to its Board of Directors

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

    $BRKR
    $PGNY
    $SIBN
    $SWAV
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Misc Health and Biotechnology Services
    Health Care
  • SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025

    SANTA CLARA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, February 24, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/xyxunb4k. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be archi

    $SIBN
    Medical/Dental Instruments
    Health Care

$SIBN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SIBN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SIBN
SEC Filings

See more

$SIBN
Leadership Updates

Live Leadership Updates

See more
  • Bruker Appoints Laura Francis to its Board of Directors

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

    $BRKR
    $PGNY
    $SIBN
    $SWAV
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Misc Health and Biotechnology Services
    Health Care
  • Mainstay Medical Announces Appointment of Jeffrey Dunn and Eric Major to its Board of Directors

    Mainstay Medical Holdings plc today announced the appointment of two new independent members to the company's board of directors, Jeffrey Dunn and Eric Major. These appointments bring Mainstay's total board membership to seven. "We are pleased to welcome these two transformational business leaders as new independent directors on the Board," said David Brabazon, Chairman of the Mainstay Board of Directors. "Their deep experience will be invaluable to Mainstay as we grow our business and pursue our mission to serve patients with intractable chronic low back pain." "As our business evolves and we continue to focus on commercial growth, broadening the industry expertise on our Board will help

    $SIBN
    Medical/Dental Instruments
    Health Care
  • SI-BONE Appoints Anshul Maheshwari as Chief Financial Officer and Announces the Addition of Helen Loh and Laura Francis to the Board of Directors

    SANTA CLARA, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the appointment of Anshul Maheshwari as the company's Chief Financial Officer effective April 20, 2021, and the addition of Helen Loh and Laura Francis to its Board of Directors effective April 18, 2021. The appointment of Mr. Maheshwari completes the recently announced senior leadership transition which includes Laura Francis succeeding Jeff Dunn as Chief Executive Officer, and Tony Recupero becoming President, Commercial Operations. Jeff Dunn will remain with the compa

    $SIBN
    Medical/Dental Instruments
    Health Care

$SIBN
Financials

Live finance-specific insights

See more
  • SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance

    SANTA CLARA, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $49.0 million, representing growth of ~26%  U.S. revenue of $46.9 million, representing growth of ~28%Gross margin of ~79%Net loss of $4.5 million, representing an improvement of ~59%Positive adjusted EBITDA of $1.9 million, representing an improvement of ~139%Ended the quarter with $150.0 million in cash and equivalents, representing $0

    $SIBN
    Medical/Dental Instruments
    Health Care
  • SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025

    SANTA CLARA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, February 24, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/xyxunb4k. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be archi

    $SIBN
    Medical/Dental Instruments
    Health Care
  • SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024

    SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, December 4, 2024, at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://event.webcasts.com/starthere.jsp?ei=1696941&tp_key=589204a98b. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast

    $SIBN
    Medical/Dental Instruments
    Health Care

$SIBN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more